POLICY STATEMENT

Contraception for Adolescents

abstract

Contraception is a pillar in reducing adolescent pregnancy rates. The American Academy of Pediatrics recommends that pediatricians develop a working knowledge of contraception to help adolescents reduce risks of and negative health consequences related to unintended pregnancy. Over the past 10 years, a number of new contraceptive methods have become available to adolescents, newer guidance has been issued on existing contraceptive methods, and the evidence base for contraception for special populations (adolescents who have disabilities, are obese, are recipients of solid organ transplants, or are HIV infected) has expanded. The Academy has addressed contraception since 1980, and this policy statement updates the 2007 statement on contraception and adolescents. It provides the pediatrician with a description and rationale for best practices in counseling and prescribing contraception for adolescents. It is supported by an accompanying technical report. Pediatrics 2014;134:e1244–e1256

INTRODUCTION

Pediatricians play an important role in adolescent pregnancy prevention and contraception. Nearly half of US high school students report ever having had sexual intercourse.1 Each year, approximately 750,000 adolescents become pregnant, with more than 80% of these pregnancies unplanned, indicating an unmet need for effective contraception in this population.2,3 Although condoms are the most frequently used form of contraception (52% of females reported condom use at last sex), use of more effective hormonal methods, including combined oral contraceptives (COCs) and other hormonal methods, was lower, at 51% and 12%, respectively, in 2011.1 Use of highly effective long-acting reversible contraceptives, such as implants or intrauterine devices (IUDs), was much lower.1

Adolescents consider pediatricians and other health care providers a highly trusted source of sexual health information.4,5 Pediatricians’ long-term relationships with adolescents and families allow them to ask about sensitive topics, such as sexuality and relationships, and to promote healthy sexual decision-making, including abstinence and contraceptive use for teenagers who are sexually active. Additionally, medical indications for hormonal contraception, such as dysmenorrhea, heavy menstrual bleeding or other abnormal uterine bleeding, acne, and polycystic ovary syndrome, are often uncovered during adolescent visits. A working knowledge of contraception will assist the pediatrician in both sexual health promotion and treatment of common...
adolescent gynecologic problems. Contraception has been inconsistently covered as part of insurance plans. However, the Institute of Medicine has recommended contraception as an essential component of adolescent preventive care, and the Patient Protection and Affordable Care Act of 2010 (Pub L No. 111–148) requires coverage of preventive services for women, which includes contraception, without a copay.

**SETTING THE STAGE**

Confidentiality and Consent

In the setting of contraception and sexual health care, the American Academy of Pediatrics (AAP) believes that policies supporting adolescent consent and protecting adolescent confidentiality are in the best interests of adolescents. Accordingly, best practice guidelines recommend confidentiality around sexuality and sexually transmitted infections (STIs) and minor consent for contraception. The majority of states have specific laws regarding minor consent to contraception (see State Minor Consent Laws: A Summary and the Guttmacher Institute’s State Center at http://www.guttmacher.org/statecenter/ for regularly updated state-by-state summaries). For states without specific laws, best practice guidelines, federal statutes, and federal case law may support minor confidentiality and consent. For example, family planning clinics funded by Title X of the federal Public Health Services Act (42 USC §§300–300a-6 (1970)) are required to provide confidential services to adolescents.

The Health Insurance Portability and Accountability Act (HIPAA [Pub L No. 104–191, 1996]) specifically addresses minor confidentiality. Although HIPAA allows parents access to a minor’s records as personal representatives, that access is denied when the minor is provided with confidentiality under state or other laws or when the parent agrees that the minor may have confidential care. Therefore, the AAP recommends that pediatricians have an office policy that explicitly describes confidential services and that pediatricians discuss (and document) confidentiality with all parents and adolescents. As an additional protection for minors’ confidentiality, HIPAA states that if there is no applicable state law about the rights of parents to access the protected health information of their children, pediatricians (or other licensed health professionals) may exercise their professional judgment to provide or deny parental access to the records.

This can be accomplished with careful documentation of their professional judgment. Insurance, billing, and electronic health record systems create additional challenges, including maintaining the confidentiality of visits, visit content, associated laboratory test results, and payment for the contraceptive method itself. For additional discussion of electronic health records, see the AAP policy statement on health information technology.

Careful attention to minor consent and confidentiality is important, because limitations on confidentiality and consent are linked to lower use of contraceptives and higher adolescent pregnancy rates. Parents need not be adversaries; in fact, many parents are supportive of minor consent and confidentiality for sexual health services. As permitted by law, adolescent contraception should be provided as a confidential service, with adolescents encouraged to involve parents or trusted adults as they are able.

**Sexual History Taking and Counseling**

Bright Futures recommends that pediatricians take a developmentally targeted sexual history, assess STI and pregnancy risk, and provide appropriate screening, counseling, and, if needed, contraceptives. Key to history taking is an honest, caring, nonjudgmental attitude and a comfortable, matter-of-fact approach to asking questions. This can be accomplished by assessing the 5 Ps of sexual history taking, as described by the Centers for Disease Control and Prevention (CDC): partners, prevention of pregnancy, protection from STIs, sexual practices, and past history of STIs and pregnancy. Counseling should draw on motivational interviewing approaches, with the focus of the interview on future goals, belief in the adolescents’ capacity to change, and engagement of the adolescent in the process of adopting health-promoting behaviors. For an example of motivational interviewing for sexual health counseling, see Ott et al (2007), and for a more detailed discussion of counseling approaches, see the accompanying technical report.
METHODS OF CONTRACEPTION

This section summarizes the contraceptive options for adolescents; the accompanying technical report provides more detailed information on each of the methods. When comparing the efficacy of different methods, it is important to distinguish between typical use and perfect use, and counseling should be based on typical use. Typical use efficacy refers to the probability of pregnancy during the first year of typical use and includes users with varying degrees of adherence; perfect use efficacy is the probability of pregnancy if used consistently and correctly every time.32 The most effective methods rely the least on individual adherence; for these methods, typical use effectiveness approaches perfect use effectiveness. Contraceptive methods most commonly used by adolescents are listed below, ordered from most to least effective, starting with long-acting reversible contraception (LARC): implants and IUDs. Pediatricians are encouraged to counsel adolescents in that order, discussing the most effective contraceptive methods first (see Table 1 for contraceptive effectiveness).

Progestin Implants

Implanon and Nexplanon (Merck, Whitehouse Station, NJ) are both single-rod implants that contain etonogestrel, the active metabolite of the progestin desogestrel. Implants, a LARC method, are highly effective, with typical and perfect use failure rates of less than 1%32,33; they may remain in place for 3 years. The implant is inserted into the inside of the upper arm by a clinician who has completed the requisite training. Implants are ideal for adolescents who prefer a method that does not require regularly scheduled adherence and who desire an extended length of protection. A common reason for discontinuation is unpredictable bleeding or spotting.34,35 Contraceptive implants can also be offered to pregnant adolescents and provided in the immediate postpartum period, while the adolescent is still in the hospital. The American College of Obstetricians and Gynecologists (ACOG) and the CDC both support immediate postpartum insertion of implants as a safe and effective practice that removes barriers to care.36,37 The main theoretical concern about contraceptive implant use in the postpartum period is whether the progestin might have some effect on breastfeeding; however, studies of contraceptive implant use among breastfeeding women have generally found no effects on breastfeeding performance or infant health and growth.38,39 When starting an implant, patients should be counseled that a backup method (ie, condoms or abstinence) should be used for at least the first week for contraceptive efficacy and that a condom should be used at all times for protection against STIs.

IUDs

IUDs inserted into the uterus also provide long-acting reversible contraception. Three IUDs currently are approved in the United States: 2 levonorgestrel-releasing T-shaped IUDs (Mirena, 52 mg levonorgestrel, and Skyla, 13.5 mg levonorgestrel; Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ) and a copper-containing T-shaped IUD (Copper T380-A, ParaGard; Teva North America, North Wales, PA). The 13.5-mg levonorgestrel IUD is approved for 3 years;40 the 52-mg levonorgestrel IUD is approved for 5 years;41 and the copper IUD is approved for 10 years.42 Despite their low but increasing use in the United States, IUDs are highly effective when used correctly and consistently.32

| Method | % of Women Experiencing an Unintended Pregnancy in the First Year of Use | % of Women Continuing Use at 1 Year |
|--------|-------------------------------------------------------------------------|------------------------------------|
|        | Typical Use<sup>a</sup> | Perfect Use<sup>b</sup> |                                |
| No method | 85  | 85 | —                      |
| Spermicides (foams, creams, gels, suppositories, and film) | 28  | 18 | 42                    |
| Fertility awareness–based methods | 24 | — | 47                    |
| Withdrawal | 22 | 4 | 46                    |
| Condom | | | |
| Female | 21 | 5 | 41                    |
| Male | 18 | 2 | 43                    |
| Diaphragm | 12 | 6 | 57                    |
| Combined pill and progestin-only pill | 9 | 0.3 | 67 |
| Contraceptive patch | 9 | 0.3 | 67 |
| Contraceptive ring | 9 | 0.3 | 67 |
| DMPA contraceptive injection | 6 | 0.2 | 56 |
| IUD | | | |
| Copper T | 0.8 | 0.6 | 78 |
| Levonorgestrel | 0.2 | 0.2 | 80 |
| Single-rod contraceptive implant | 0.05 | 0.05 | 84 |
| Female sterilization | 0.5 | 0.5 | 100 |
| Male sterilization | 0.15 | 0.10 | 100 |

<sup>a</sup> Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 y.

<sup>b</sup> Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, periodic abstinence, the diaphragm, the male condom, the pill, and Depo-Provera are taken from the 1995 and 2002 National Survey of Family Growth, corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods.

<sup>c</sup> Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.
States, IUDs are used extensively worldwide because they are safe and effective methods of contraception with typical and perfect use failure rates of less than 1%.45 The copper IUD can be used as emergency contraception (EC) within 5 days of unprotected intercourse.43,44 Despite past concerns, IUDs are now known to be safe for nulliparous adolescents. IUDs themselves do not cause tubal infertility in nulliparous women,45 and studies support a rapid return to fertility after IUD removal.46,47 The risk of pelvic infection with IUDs occurs only during insertion. Beyond the first 21 days, IUDs do not increase rates of STIs or pelvic inflammatory disease (PID).48,49 Unless the adolescent is at very high risk for STIs (eg, had sex with a partner with known gonorrhea), screening for gonorrhea and chlamydia can be performed on the day of insertion.50 Treatment, if needed, can be subsequently provided without IUD removal, because studies have demonstrated that, provided the patient improves with treatment, both STIs and PID can be treated with the IUD in place.51,52 Contraindications to IUD placement are limited to current purulent cervicitis, gonorrhea, or chlamydia, current PID and other current pelvic infections (see “US Medical Eligibility Criteria for Contraceptive Use” for more extensive discussion).37 Past PID is not a contraindication to IUD use. HIV infection and immunosuppression are also not contraindications to IUD use. IUDs can also be offered to pregnant adolescents and provided in the immediate postpartum period, while the adolescent is still in the hospital. Two systematic reviews concluded that immediate postpartum insertion of IUDs is safe and effective.53,54 and both ACOG and the CDC support this practice.36,37,55 Studies have shown that many women who desire an IUD at the time of delivery do not return for later insertion and that immediate insertion of IUDs provides similar contraceptive coverage as delayed insertion, even with higher expulsion rates with immediate insertion.36,57 The emerging adolescent-specific data on IUDs are promising. However, there are some disadvantages. The limited data in adolescents suggest that expulsion, which occurs in fewer than 5% of women using IUDs, may occur more frequently in younger women.58 Another concern is that more than half of young nulliparous women report moderate to severe pain with insertion.59,60 Nonetheless, studies demonstrate IUD continuation rates in adolescents that exceed those with other hormonal methods and effective use of the levonorgestrel IUD for menstrual suppression in adolescent patients with complex medical conditions.61–67

**Progestin-Only Injectable Contraception**

Depot medroxyprogesterone acetate (DMPA, also known by the brand name Depo-Provera; Pfizer, New York, NY) is a long-acting progestin that is given as a single injection every 13 weeks (up to 15 weeks) using a dose of either 150 mg delivered intramuscularly or 104 mg delivered subcutaneously. Many health care providers schedule visits every 11 to 12 weeks for adolescents to allow for missed or delayed visits. Both regimens have similar effectiveness and side effects68 and are highly effective in preventing pregnancy. In the first year of use, the probability of becoming pregnant with typical use is approximately 6%.52 DMPA can be initiated on the same day as the visit (“mid-cycle” or “quick” start) as long as the health care provider is reasonably certain the adolescent is not pregnant. For additional details, see the accompanying technical report and the CDC’s 2013 “US Selected Practice Recommendations for Contraceptive Use.”75 DMPA is convenient for many adolescents because of its ease of use. Other advantages include improvement in dysmenorrhea and protection against iron deficiency anemia and endometrial cancer.69,70 DMMA is safe for most patients with chronic illness,37 is thought to raise the seizure threshold in adolescents with epilepsy,71,72 and may decrease sickle cell crises.71,72 The major disadvantages of DMPA include the need for an injection every 13 weeks and the menstrual cycle irregularities that are present for nearly all patients initially. These menstrual irregularities typically improve over time73,74 and may be less likely to result in discontinuation if patients are counseled about these effects before the first injection.75,76 Other possible adverse effects include headache, mastalgia, hair loss, change in libido, and weight gain. Studies in both adolescents77 and adults78 suggest that weight gain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use, but that weight gain does not occur in all patients.79,80 DMPA causes reductions in bone mineral density (BMD).81–83 and in 2004 the US Food and Drug Administration (FDA) issued a black-box warning about the risk of decreased BMD among DMPA users.84 Subsequent publications document a substantial recovery of BMD after the patient discontinues DMPA,85–87 and ACOG, recognizing the risk of unwanted pregnancy if women’s contraceptive options are limited, does not advise limiting DMPA use to 2 years (in contrast to earlier concerns88) or routinely monitoring bone density after that time frame.89 Nonetheless, it remains...
important to consider other risk factors for osteoporosis and to tailor counseling and recommendations to each patient. All patients should be counseled about measures that promote skeletal health, such as daily intake of 1300 mg of calcium and 600 IU of vitamin D and regular weight-bearing exercise.90

Combined Oral Contraceptive Pills

COCs are the most popular method of hormonal contraception for adolescents. COCs all contain a progestin and an estrogen. In almost every pill, the estrogen component is ethinyl estradiol in amounts varying from 10 to 50 μg. Many adolescent medicine experts begin with a COC containing 30 to 35 μg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate. However, any “low-dose” pill (ie, containing ethinyl estradiol 35 μg or less ) can be used. Although inspection of the external genitalia and a vaginal swab or urine screen for STIs are recommended practices in the care of sexually active patients,91 no gynecologic examination is needed to determine eligibility for COC use. Like other combined methods including the contraceptive vaginal ring and transdermal patch, COCs can be started on the same day as the visit (“quick start”) in healthy, nonpregnant adolescents. Patients should be counseled that a backup method (ie, condoms or abstinence) should be used for at least the first 7 days for contraceptive efficacy and that a condom should be used at all times for protection against STIs. The CDC recommends prescribing up to 1 year of COCs at a time.52 Additionally, a routine follow-up visit 1 to 3 months after initiating COCs is useful for addressing adverse effects or adherence issues.

COCs have few contraindications in healthy female adolescents. They should not be prescribed for patients with severe and uncontrolled hypertension (systolic pressure ≥160 mm Hg or diastolic pressure ≥100 mm Hg), ongoing hepatic dysfunction, complicated valvular heart disease, migraines with aura or focal neurologic symptoms, thromboembolism or thrombophilia, complications of diabetes (ie, nephropathy, retinopathy, neuropathy, or other vascular disease), and complicated solid organ transplantation.57 The most serious adverse event associated with COC use is the increased risk of blood clots, which increases from 1 per 10 000 to 3 to 4 per 10 000 woman-years during COC use.92,93 In comparison, the incidence of venous thromboembolism associated with pregnancy and postpartum is 10 to 20 per 10 000 woman-years, of which 1% to 2% are fatal.94,95 Although smoking should be discouraged, it is not a contraindication to COC use in teenagers and adults younger than 35 years old.57

Patients should be informed that common transient adverse effects of COCs include irregular bleeding, headache, and nausea. Recommendations for managing adverse effects have been published elsewhere96 or can be found online (http://www.managingcontraception.com/qa/index.php or http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s_cid=rr6205a1_w#Fig2).52 Drug interactions should also be avoided. With medications that decrease COC effectiveness (eg, anti-convulsants and antiretroviral drugs), patients may benefit from choosing an alternative method or dosing97 (see the accompanying technical report for additional details). Most broad-spectrum antibiotics (rifampin is an exception) do not affect the contraceptive effectiveness of COCs.57

Typical use failure rates are 9% in adults and may be higher in adolescents.32,98 Counseling should include strategies to promote daily adherence, such as cell phone alarms and support from a family member or partner. Patients should be instructed on what to do if pills are missed. A missed pill should be taken as soon as it is remembered. If more than 1 pill in a row is missed, only the most recently missed pill should be taken as soon as possible, and the remaining pills should be taken at the usual time. Patients should be reminded that 7 consecutive hormone pills are needed to prevent ovulation. Additional instructions can be accessed online (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s_cid=rr6205a1_w#Fig2). EC is indicated if 2 or more pills are missed in the first week of the cycle.96,100 EC should also be considered if 1 or more pills were missed earlier in the same cycle as a missed pill or late in the previous cycle (see online instructions provided earlier for details).

Many patients may benefit from decreasing or eliminating the hormone-free (placebo) interval. Extended or continuous cycles may be useful for treating medical conditions such as anemia, acne, severe dysmenorrhea, endometriosis, dysfunctional or heavy menstrual bleeding, Von Willebrand disease, and other bleeding diatheses and for adolescents who prefer amenorrhea.101 These regimens may also be useful for conditions that can be exacerbated cyclically, such as migraine (without aura), epilepsy, irritable bowel syndrome, inflammatory bowel disease, and some psychiatric and behavioral symptoms102; the most common adverse effect of extended or continuous cycles is unscheduled bleeding. Patients may be reassured to know that observational data indicate that COC use does not increase the risk of infertility or breast cancer103 and that use of COCs for more than 4 years provides significant protection against endometrial and ovarian cancers.104

Contraceptive Vaginal Ring

The vaginal ring (NuvaRing; Merck, Whitehouse Station, NJ) releases a combination...
of estrogen and progestin and thus has the same eligibility criteria for use as COCs. As with COCs, a same-day start (“quick start”) can also be used with the vaginal ring. The ring is inserted in the vagina and stays in place for 3 weeks, with removal for 1 week to induce withdrawal bleeding, followed by insertion of a new ring. Patients should be instructed to insert a new ring after 7 days even if bleeding has not ceased.

The ring has comparable efficacy, risks, and benefits as other combined hormonal methods but provides the simplest regimen. Adverse effects are also similar, with the additional vaginal symptoms of discharge, discomfort, and problems related to the device (eg, expulsion). The ring is an excellent method for extended use because, although labeled for 28 days of use, the rings contain sufficient medication to be used for up to 35 days and thus can be replaced once every calendar month. Sexually active patients may be reassured to know that most men were not bothered by its presence, if it was noted at all.

Transdermal Contraceptive Patch

The combination hormone (estrogen and progestin) transdermal contraceptive patch (Ortho Evra; Ortho-McNeil Pharmaceutical, Raritan, NJ) is placed on the abdomen, upper torso, upper outer arm, or buttocks using 1 patch for each of 3 weeks in a row, followed by 1 week off the patch, during which a withdrawal bleed usually occurs. Typical use failure rates are similar to those of COCs at 9%. The FDA has identified increased estrogen exposure (1.6 times higher than with a low-dose COC) and a potential increased risk of venous thromboembolism with the patch (see accompanying technical report for more complete discussion).

The patch has comparable efficacy, benefits, eligibility criteria for use, and drug interactions as COCs; side effects are similar to those of other combined methods, with the addition of dislodged patches and skin effects, such as hyperpigmentation, contact dermatitis, and other irritation. The risk of pregnancy with correct (“perfect”) use of the patch is slightly higher for women who weigh more than 198 pounds than for women who weigh less (0.9% vs 0.3% in first 12 months of use).

Progestin-Only Pills

Progestin-only pills (also known as “mini-pills”) work primarily by thickening cervical mucus, not by inhibiting ovulation. Because very stringent adherence is necessary, their failure rate can be significantly higher than those of other combined hormonal and progestin-only methods (IUDs and contraceptive implants and injections). However, they provide an additional option for patients who have safety concerns about estrogen use (see accompanying technical report for additional details).

Emergency Contraception

In the United States, EC is available as oral levonorgestrel; an oral progesterone receptor modulator, ulipristal acetate; high-dose combined estrogen–progestin oral contraceptive pills (the Yuzpe regimen); and placement of a copper IUD. Levonorgestrel EC is preferred to the Yuzpe regimen because of the superior adverse effect profile and effectiveness, which is up to 85%.

Ulipristal acetate may have greater effectiveness than oral levonorgestrel at the end of the 5-day window of use, and its remaining effectiveness and adverse effect profile are similar to those of levonorgestrel. In addition, on the basis of recent data about lower efficacy of levonorgestrel EC, ulipristal may be more effective in people who weigh more than 165 pounds. Placement of a copper-bearing IUD is less commonly used for EC in adolescents but is the most effective EC method, with a failure rate of less than 1%.

The recommended dosage of levonorgestrel is a single 1.5-mg dose. It is available either as 2 pills (0.75 mg each) or as 1 pill (Plan B One-Step; Teva Pharmaceuticals, Petah Tikva, Israel). Levonorgestrel-based EC delays or inhibits ovulation and does not
appear to be effective once ovulation has occurred. If used inadvertently during early pregnancy, it is not teratogenic, only ineffective. Thus, a pregnancy test is not mandatory before levonorgestrel EC is prescribed.

Plan B One-Step is approved by the FDA as a nonprescription product for all women of childbearing potential. Generic versions are approved as a nonprescription product for women 17 years of age and older; however, proof of age is not required to purchase them. Providing EC in advance increases the likelihood of use when it is needed without increasing sexual or contraceptive risk-taking behavior. Therefore, EC should be prescribed or recommended in advance for use for up to 5 days after an event of unprotected intercourse. Additional details on EC mechanisms and use can be found in the AAP policy statement on emergency contraception and the accompanying technical report.

Withdrawal
Withdrawal, or coitus interruptus, is a method in which the male partner attempts to pull out his penis before ejaculation. Because 57% of female adolescents report using withdrawal, pediatricians should ask about it. However, because of its limited effectiveness (22% failure rate among all users) and lack of STI protection, pediatricians should encourage adolescents to adopt more effective methods.

Other Methods
The female condom, periodic abstinence (fertility awareness or “the rhythm method”), vaginal spermicides, the cervical cap, and the diaphragm are methods less commonly used by adolescents. Additional descriptions are available in the accompanying technical report.

SPECIAL POPULATIONS
Adolescents With Disabilities and Medically Complex Illness
An estimated 16% to 25% of adolescents are identified as having special health care needs, including physical disability, developmental disability, and medically complex illness. The improved survival of adolescents with medically complex illnesses, such as disabilities, chronic disease, HIV, and solid organ transplants, has prompted greater attention to quality-of-life issues. These issues, including adolescent interest in romantic and sexual relationships, are typically addressed by a pediatrician. Sexuality and sexual health care needs in this population are often overlooked, yet data demonstrate that, compared with healthy adolescents, adolescents with chronic illness have similar levels of sexual behaviors and sexual health outcomes (eg, STIs). In addition to pregnancy prevention, these adolescents may need menstrual suppression for heavy menstrual bleeding, bleeding disorders, or chemotherapy. Other patients may be using teratogenic medications and need contraception for that reason. Issues that arise include safety concerns with estrogen use, medication interactions, and complications from the underlying disease. The CDC has recently addressed the contraceptive needs of young women with medical conditions by publishing the “US Medical Eligibility Criteria for Contraceptive Use.” Available online, this document summarizes the literature on safety and efficacy of different contraceptive methods by medical condition. Additional details on specific populations (eg, those with disabilities) are summarized in the accompanying technical report.

Adolescents With Obesity
The sexual health needs and sexual behaviors of adolescents with obesity are substantially similar to those of their normal-weight peers. In addressing contraception, it is important to note that obesity and related endocrine effects can influence the efficacy and adverse effects profiles of contraceptives. For example, a small number of excess pregnancies were found among transdermal contraceptive patch users weighing more than 90 kg (198 lb). The World Health Organization and CDC report that data are limited and inconsistent about whether CDC effectiveness varies by body weight or BMI. A common concern of both adolescents and providers is additional weight gain among adolescents with obesity after they start contraception. Data suggest that women with obesity are no more likely to gain weight with COCs, the vaginal ring, IUDs, or implants than normal-weight peers. In contrast, adolescents with obesity who used DMPA were more likely than nonusers with obesity, COC users with obesity, and normal-weight DMPA users to gain weight. Increasing numbers of adolescents are having bariatric surgery procedures performed, and these patients need highly effective contraception. Post-surgery data reveal an improvement in fertility coupled with the potential for decreased contraceptive effectiveness through malabsorption, vomiting, and diarrhea. Professional consensus statements recommend delaying pregnancy for at least 12 months after the procedure. All contraceptive methods are safe for women with a history of bariatric surgery, with the exception of oral contraceptives for women who have undergone malabsorptive procedures. There is increasing experience and success with the levonorgestrel IUD placed at the time of surgery.

ADHERENCE AND FOLLOW-UP
Frequent follow-up is important to maximize adherence for all methods of contraception and to promote and
reinforce healthy decision-making. Adolescents count on trusted health professionals, such as pediatricians, for support and problem solving around continuation and adherence. Regularly scheduled contraceptive follow-up visits should address use, adherence, adverse effects, and complications. Pediatricians can use motivational interviewing approaches to increase effective and consistent contraceptive use, including engaging parental support for contraceptive adherence, when possible. Follow-up visits should additionally include reassessment of relationships, sexual behaviors, contraceptive needs, STI surveillance and prevention, and other sexual health prevention measures, such as human papillomavirus immunization.

**RECOMMENDATIONS**

1. Pediatricians should counsel about and ensure access to a broad range of contraceptive services for their adolescent patients. This includes educating patients about all contraceptive methods that are safe and appropriate for them and describing the most effective methods first.

2. Pediatricians should be able to educate adolescent patients about LARC methods, including the progesterin implant and IUDs. Given the efficacy, safety, and ease of use, LARC methods should be considered first-line contraceptive choices for adolescents. Some pediatricians may choose to acquire the skills to provide these methods to adolescents. Those who do not should identify health care providers in their communities to whom patients can be referred.

3. Despite increased attention to adverse effects, DMPA and the contraceptive patch are highly effective methods of contraception that are much safer than pregnancy. Pediatricians should continue to make them available to their patients.

4. Pediatricians should allow the adolescent to consent to contraceptive care and to control the disclosure of this information within the limits of state and federal laws. There are a number of supports for protecting minor consent and confidentiality, including state law, federal statutes, and federal case law. Pediatricians will need to be familiar with national best practice recommendations for confidential care and with the relevant minor consent laws in their states.

5. Pediatricians should be aware that it is appropriate to prescribe contraceptives or refer for IUD placement without first conducting a pelvic examination. Screenings for STIs, especially chlamydia, can be performed without a pelvic examination and should not be delayed.

6. Pediatricians should encourage the consistent and correct use of condoms with every act of sexual intercourse.

7. Pediatricians should have a working knowledge of the different combined hormonal methods and regimens, because these provide excellent cycle control both for contraception and medical management of common conditions, such as acne, dysmenorrhea, and heavy menstrual bleeding.

8. Pediatricians should remember that adolescents with chronic illness and disabilities have similar sexual health and contraceptive needs to healthy adolescents while recognizing that medical illness may complicate contraceptive choices.

9. Pediatricians should regularly update their adolescent patients’ sexual histories and provide a confidential and nonjudgmental setting in which to address needs for contraception, STI screening, and sexual risk reduction counseling for patients who choose not to be abstinent.

10. Pediatricians should allow sufficient time with their adolescent patients to address contraceptive needs using a developmentally appropriate, patient-centered approach, such as motivational interviewing. If necessary, arrangements should be made for a separate visit for contraceptive follow-up to increase adherence and monitor for adverse effects and complications.

11. Pediatricians can complement the skills and resources of the pediatric office by being aware of state or federally subsidized insurance programs and clinics that provide confidential and free or low-cost reproductive health care services and supplies, including contraception.

**LEAD AUTHORS**

Mary A. Ott, MD, MA, FAAP
Gina S. Sucato, MD, MPH, FAAP

**COMMITTEE ON ADOLESCENCE, 2013–2014**

Paula K. Braverman, MD, Chairperson
William P. Adelman, MD, FAAP
Elizabeth M. Alderman, MD, FAAP, FSHAM
Cora C. Breuner, MD, MPH, FAAP
David A. Levine, MD, FAAP
Arik V. Marcell, MD, FAAP
Rebecca F. O’Brien, MD, FAAP

**PAST COMMITTEE MEMBER**

Pamela J. Murray, MD, MPH, FAAP

**LIAISONS**

Loretta E. Gavin, PhD, MPH – Centers for Disease Control and Prevention
Margie Lane, MD, FRCPC – Canadian Pediatric Society
Rachel J. Miller, MD – American College of Obstetricians and Gynecologists
Benjamin Shain, MD, PhD – American Academy of Child and Adolescent Psychiatry

**STAFF**

Karen S. Smith
James D. Baumberger, MPP
REFERENCES

1. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010 national survey of family growth. Vital Health Stat 23. 2011; (31):1–35

2. Kost K, Henshaw S, Carlin L. US Teenage Pregnancies, Births and Abortions: National and State Trends and Trends by Race and Ethnicity. New York, NY: Guttmacher Institute; 2010

3. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(5):478–485

4. Ott MA, Rosenberger JG, McBride KR, Woodcox SG. How do adolescents view health? Implications for state health policy. J Adolesc Health. 2011;48(4):398–403

5. Jones RK, Biddlecom AE. The more things change…: the relative importance of the internet as a source of contraceptive information for teens. Sex Res Soc Policy. 2011;9(1):27–37

6. Institute of Medicine, Committee on Preventive Services for Women. Clinical Preventive Services for Women: Closing the Gaps. Washington, DC: National Academies Press; 2011

7. Health Resources and Services Administration. Women’s Preventive Services: Required Health Plan Coverage Guidelines. Rockville, MD: Health Resources and Services Administration; 2012

8. The Patient Protection and Affordable Care Act. Pub L No. 111-148 (2010). Available at: www.healthcare.gov.

9. Ford C, English A, Sigman G. Confidential Health Care for Adolescents: position paper for the society for adolescent medicine. J Adolesc Health. 2004;35(2):160–167. Available at: www.adolescenthealth.org/SAHM_Main/media/Advocacy/Positions/Aug-04-Confidential_Health_Care_for_Adolescents.pdf. Accessed June 22, 2014

10. American College of Obstetricians and Gynecologists. Guidelines for Adolescent Health Care. Washington, DC: American College of Obstetricians and Gynecologists; 2011

11. American Academy of Pediatrics, Committee on Adolescence. Policy statement: achieving quality health services for adolescents. Pediatrics. 2008;121(6):1263–1270. Available at: http://pediatrics.aappublications.org/content/121/6/1263.full.pdf+html. Accessed June 22, 2014

12. Center for Adolescent Health and the Law. State Minor Consent Laws: A Summary. 3rd ed. Chapel Hill, NC: Center for Adolescent Health and the Law; 2010

13. Guttmacher Institute. An overview of minors’ consent law. State policies in brief as of June 1, 2014. Available at: www.guttmacher.org/statecenter/spibs/spib_MACS.pdf. Accessed June 20, 2014

14. English A, Ford CA. The HIPAA privacy rule and adolescents: legal questions and clinical challenges. Perspect Sex Reprod Health. 2004;36(2):80–88

15. Spooner SA, Council on Clinical Information Technology, American Academy of Pediatrics. Special requirements of electronic health record systems in pediatrics. Pediatrics. 2007;119(3):631–637 http://pediatrics.aappublications.org/content/119/3/631.full.pdf+html. Accessed June 22, 2014

16. Council on Clinical Information Technology. Health information technology and the medical home. Pediatrics. 2011;127(5):978–982. Available at: http://pediatrics.aappublications.org/content/127/5/978.full.pdf+html. Accessed June 22, 2014

17. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls’ use of sexual health care services. JAMA. 2002;288(6):710–714

18. Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and nonclinic populations compared. J Adolesc Health. 1991;12(3):225–232

19. Guidi M. Fertility effects of abortion and birth control pill access for minors. Demography. 2008;45(4):827–827

20. Zavodny M. Fertility and parental consent for minors to receive contraceptives. Am J Public Health. 2004;94(8):1347–1351

21. Lehrer JA, Pantell R, Tebb K, Shafer MA. Forgone health care among U.S. adolescents: associations between risk characteristics and confidentiality concern. J Adolesc Health. 2007;40(3):218–226

22. Dempsey AF, Singer DD, Clark SJ, Davis MM. Adolescent preventive health care: what do parents want? J Pediatr. 2009;155(5):689.e1–694.e1

23. Jones RK, Purcell A, Singh S, Finer LB. Adolescents’ reports of parental knowledge of adolescents’ use of sexual health services and their reactions to mandated parental notification for prescription contraception. JAMA. 2005;293(5):340–348

24. Hagan JF, Shaw JS, Duncan PM, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. Elk Grove Village, IL: American Academy of Pediatrics; 2008. Available at: http://brightfutures.aap.org/pdfs/Guidelines_PDF/18-Adolescence.pdf. Accessed June 22, 2014

25. Centers for Disease Control and Prevention. A Guide to Taking a Sexual History. Atlanta, GA: Centers for Disease Control and Prevention; 2005. Available at: www.cdc.gov/std/treatment/SexualHistory.pdf. Accessed June 22, 2014

26. Blum RW. Healthy youth development as a model for youth health promotion. A re-evaluation. J Adolesc Health. 1998;22(5):368–375

27. Ott MA, Labbett RL, Gold MA. Counseling adolescents about abstinence in the office setting. J Pediatr Adolesc Gynecol. 2007;20(1):39–44

28. American Academy of Pediatrics, Committee on Adolescence. Technical report: contraception for adolescents. Pediatrics. 2014; (in press)

29. Bruckner H, Bearman P. After the promise: the STD consequences of adolescent virginity pledges. J Adolesc Health. 2005; 36(4):271–278

30. Pinkerton SD. A relative risk-based, disease-specific definition of sexual abstinence failure rates. Health Educ Behav. 2001; 28(1):10–20

31. Committee on Adolescence. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth. Pediatrics. 2013;132(1):198–203. Available at: http://pediatrics.aappublications.org/content/132/1/198.full.pdf. Accessed June 22, 2014

32. Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS. Contraceptive Technology. 20th rev ed. Valley Stream, NY: Ardent Media; 2011

33. Graeslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(suppl 1):4–12

34. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74(4):287–289

35. Harvey C, Seib C, Luke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80(6):527–532

36. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception.
contraception: implants and intrauterine devices. Obstet Gynecol 2012;120(4):983–988

37. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;59(RR-4):1–6. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s_cid=rr5904a1_e. Accessed June 22, 2014

38. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol 2011;117(5):1114–1121

39. Kapp N, Curtis K, Nanda K. Progestogen-only contraceptive use among breast-feeding women: a systematic review. Contraception 2010;82(1):17–37

40. Bayer HealthCare Pharmaceuticals. Skyla package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Accessed January 13, 2014

41. Bayer HealthCare Pharmaceuticals. Mirena package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed January 13, 2014

42. Teva Women’s Health Inc/Teva Pharmaceuticals. Paragard package insert. Sellersville, PA: Teva Woman’s Health Inc/Teva Pharmaceuticals; 2011. Available at: http://paragard.com/Pdf/ParaGuard-Pi.pdf. Accessed June 22, 2014

43. Trussell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. Contraception. 2012;85(6):611

44. Committee on Adolescence. Emergency contraception. Pediatrics. 2012;130(6):1174–1182

45. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–567

46. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility: follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88–92

47. Penney G, Brechin S, de Souza A, et al; Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPFRHC guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plan Reprod Health Care. 2004;30(1):29–41, quiz 42

48. Mohilajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006;73(2):145–153

49. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–788

50. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184–196

51. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356(9234):1013–1019

52. Centers for Disease Control and Prevention. US selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition. MMWR Recomm Rep. 2013;62(RR-5):1–60

53. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2010; (5):CD003036

54. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception. 2009;80(4):327–335

55. American College of Obstetricians and Gynecologists. Increasing use of contraceptive-implants and intrauterine devices to reduce unintended pregnancy. ACOG committee opinion no. 450. Obstet Gynecol. 2009;114(6):1434–1458

56. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental Provera or Microgynon on the painful cramps of sickle cell anemia patients. J Reprod Med. 1997;56(5):1917–1918

57. Utterback KM, Myers AS,6. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6202a2.htm. Accessed August 24, 2011

58. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2009;58(RR-3):1–12

59. Pillai M, O’Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. BJOG. 2010;117(2):216–221

60. Toma A, Jamieson MA. Revisiting the intrauterine contraceptive device in adolescents. J Pediatr Adolesc Gynecol. 2006;19(4):291–296

61. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7–17

62. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1998;41(S suppl):419–427

63. Herzog AG. Progestosterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999;52(9):1917–1918

64. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997;56(5):315–316

65. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007; (2):CD006261
73. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80(2):113–118
74. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74(3):234–238
75. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception. 1999;60(6):345–351
76. Canto De Ceuna TE, Canto P, Ordonez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot medroxyprogesterone acetate. Contraception. 2001;63(5):143–146
77. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol. 2011;117(4):795–797
78. Le YC, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112(4):788–789
79. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24(6):433–436
80. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160(1):40–45
81. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1998;129(5):671–676
82. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17(1):17–21
83. Cromer BA, Stagner M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35(6):434–441
84. Pfizer. DepoProvera 150 mg and DepoSubQ Provera 104 package inserts. Cambridge, MA: Pfizer; 2005
85. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159(2):139–144
86. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81(4):281–291
87. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112(4):788–789
88. US Pharmaceuticals/Pfizer Inc. Letter to health care professionals. November 18, 2004. Available at: www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM1663505.pdf. Accessed January 13, 2014
89. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 415: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;112(3):727–730
90. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010. Available at: www.iom.edu/Reports/2010/Dietary-Reference-IntakesforCalcium-and-Vitamin-D.aspx
91. Braverman PK, Breech L; Committee on Adolescence. American Academy of Pediatrics. Clinical report: gynecologic examination for adolescents in the pediatric office setting. Pediatrics. 2010;126(3):583–590. Available at: http://pediatrics.aappublications.org/content/126/3/583.full.pdf+html. Accessed June 22, 2014
92. Trenor CC III, Chung RJ, Michelson AD, et al. Retrospective analysis of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16(3):469–475
93. Suçato GS, Gold MA. Extended cycling of oral contraceptive pills for adolescents. J Pediatr Adolesc Gynecol. 2002;15(5):325–327
94. Suçato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. Curr Opin Obstet Gynecol. 2005;17(5):461–465
95. ACOG Committee on Practice Bulletins—Gynecology. ACOG practice bulletin no. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2008;107(6):1453–1472
96. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1988–2004. Br J Cancer. 2006;95(3):385–389
97. Roumen FJ, Apted D, Mulders TM, Dieben TD. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16(3):469–475
98. Dieben TD, Roumen FJ, Apted D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100(5):585–595
99. Edwards J, Jamshidi R. The contraceptive vaginal ring. Semin Reprod Med. 2010;28(2):135–159
100. Boardman J, Mulders TM. Pharmacokinetics of etonogestrel and ethinyl estradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39(3):233–242
101. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception—oral versus intravaginal—on the sexual life of women and their partners. Hum Reprod. 2005;20(4):1100–1106
110. Veres S, Miller L, Bunting B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004;104(3):535–543

111. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(2):168–174

112. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339–346

113. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81(5):408–413

114. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progesterin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005;18(2):85–90

115. Rubinstein ML, Halperin-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004;34(5):395–401

116. Stricker T, Sennhauser FH. Allergic contact dermatitis due to transdermal contraception patch. J Pediatr. 2008;148(8):845

117. Audet MC, Moreau M, Kolton WD, et al. ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285(18):2347–2354

118. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2 Suppl 2):S13–S18

119. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454–461

120. Gallo MF, Steiner MJ, Warner L, et al. Self-reported condom use is associated with reduced risk of chlamydia, gonorrhea, and trichomoniasis. Sex Transm Dis. 2007;34(10):829–833

121. Warner L, Macaluso M, Newman D, et al. Condom effectiveness for prevention of C trachomatis infection. Sex Transm Infect. 2006;82(5):265

122. Paz-Bailey G, Kourmans EH, Sterberg M, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med. 2005;159(6):536–542

123. Nicolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect. 2005;81(4):325–327

124. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1):CD002555

125. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169(13):1255–1260

126. Stanaway JD, Wald A, Martin ET, Gottlieb SL, Magaret AS. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis. 2012;39(5):388–393

127. Winer RL, Hughes JP, Feng Q, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection in young women. N Engl J Med. 2008;354(25):2645–2654

128. Shew ML, Fortenberry JD, Tu W, et al. Condom use and the risk of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151–156

129. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis. 2009;36(7):401–405

130. Matson PA, Adler NE, Millstein SG, Tschann JM, Ellen JM. Developmental changes in condom use among urban adolescent females: influence of partner context. J Adolesc Health. 2011;48(4):386–390

131. Bearinger LH, Sieving RE, Duke NN, McMorris BJ, Stoddard S, Pettingell SL. Adolescent condom use consistency over time: global versus partner-specific measures. Nurs Res. 2011;60(3 suppl):S83–S87

132. Kenyon DB, Sieving RE, Jerstad SJ, Pettingell SL, Skay CL. Individual, interpersonal, and relationship factors predicting hormonal and condom use consistency among adolescent girls. J Pediatr Health Care. 2010;24(4):241–249

133. American Academy of Pediatrics, Committee on Adolescence. Policy statement: condom use by adolescents. Pediatrics. 2013;132(5):975–981

134. Cheng L, Gülmezoglu AM, Piaggio G, Eczurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008; (2):CD001324

135. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010;115(2 Pt 1):257–263

136. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555–562

137. Rockoff JD. FDA reviewing efficacy of Plan B contraception in women over 165 pounds. The Wall Street Journal. November 25, 2013. Available at: http://online.wsj.com/news/articles/SB1000142405270-203041034079220535719517944. Accessed January 13, 2014

138. Glasier A, Cameron ST, Bithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–367

139. Cleland K, Zhu H, Goldstick N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000

140. von Hertzen H, Piaggio G, Ding J, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002;360(9348):1803–1810

141. Gallo ME, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen–progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol. 2004;103(2):359–373

142. US Food and Drug Administration. FDA approves Plan B One-step emergency contraceptive for use without a prescription for all women of child-bearing potential. June 20, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/Announcements/ucm358082.htm. Accessed January 13, 2014

143. Ellerton C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol. 2001;98(4):570–575

144. Meyer JL, Gold MA, Haggerty CL. Advance provision of emergency contraception
145. Bethell CD, Read D, Blumberg SJ, Newacheck PW. What is the prevalence of children with special health care needs? Toward an understanding of variations in findings and methods across three national surveys. *Matern Child Health J*. 2008;12(1):1–14

146. McRee AL, Haydon AA, Halpern CT. Reproductive health of young adults with physical disabilities in the U.S. *Prev Med*. 2010;51(6):502–504

147. Suris JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. *J Adolesc Health*. 1996;19(2):124–131

148. Akers AY, Lynch CP, Gold MA, et al. Exploring the relationship among weight, race, and sexual behaviors among girls. *Pediatrics*. 2008;124(5). Available at: www.pediatrics.org/cgi/content/full/124/5/e913

149. Mond J, van den Berg P, Boutilier K, Hannan P, Neumark-Sztainer D. Obesity, body dissatisfaction, and emotional well-being in early and late adolescence: findings from the project EAT study. *J Adolesc Health*. 2011;48(4):373–378

150. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. *Obstet Gynecol*. 2012;120(1):21–26

151. Hormonal contraceptives for contraception in overweight or obese women. *Obstet Gynecol*. 2010;116(5):1206–1207

152. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. *Am J Epidemiol*. 2007;166(11):1306–1311

153. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. *Obstet Gynecol*. 2009;113(6):1306–1311

154. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. *J Womens Health (Larchmt)*. 2011;20(4):533–538
Contraception for Adolescents
COMMITTEE ON ADOLESCENCE

Pediatrics 2014;134;e1244; originally published online September 29, 2014;
DOI: 10.1542/peds.2014-2299

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/134/4/e1244.full.html